Non ST Segment Elevation Acute Coronary Syndrome Clinical Trial
Official title:
Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients
Rationale: Dual antiplatelet therapy, consisting of aspirin and a P2Y12-inhibitor, reduces the risk of stent thrombosis, myocardial infarction and stroke after coronary stent implantation. Inevitably, it is also associated with a higher risk of (major) bleeding. Given the advances in stent properties, stenting implantation technique and pharmacology, it may be possible to treat patients with a single antiplatelet strategy by completely omitting aspirin. Objective: This study will assess whether omitting aspirin reduces the rate of major or minor bleeding while remaining non-inferior to the current standard of care with regards to ischemic events in patients with non-ST segment elevation acute coronary syndrome. Study design: Open-label, multicentre randomized controlled trial. Study population: Adult patients presenting with non-ST segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. Intervention: In the intervention group aspirin will be completely omitted from the antiplatelet regimen in the 12 months following PCI. Main study endpoints: The primary bleeding endpoint is major or minor bleeding defined as Bleeding Academic Research Consortium type 2, 3 or 5 bleeding at 12 months. The primary ischemic endpoint is ischemic events defined as the composite of all-cause death, myocardial infarction and stroke at 12 months.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Recruiting |
NCT05117866 -
Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study
|
N/A | |
Recruiting |
NCT02578537 -
COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS
|
Phase 4 | |
Recruiting |
NCT06051110 -
Individual Patient Data Meta-analysis on Prehospital Risk Assessment in Patients Suspected of Non-ST-segment Elevation Acute Coronary Syndrome
|
N/A | |
Withdrawn |
NCT03300167 -
Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling
|
N/A | |
Terminated |
NCT02071966 -
Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS
|
Phase 4 | |
Not yet recruiting |
NCT06096909 -
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
|
N/A | |
Recruiting |
NCT03863327 -
EKG Criteria and Identification of Acute Coronary Occlusion
|
||
Completed |
NCT04400500 -
Differential Diagnosis and Risk Stratification in Patients With Suspected NSTEACS
|
||
Completed |
NCT01962428 -
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
|
Phase 4 | |
Recruiting |
NCT04476173 -
ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction
|
Phase 3 | |
Recruiting |
NCT06255678 -
Angio-based Final Functional Effect of PCI
|
||
Not yet recruiting |
NCT06197724 -
MCG for Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients
|
||
Recruiting |
NCT05250596 -
COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)
|
Phase 2 | |
Completed |
NCT02073565 -
HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt
|
N/A | |
Completed |
NCT04766437 -
Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy
|
Phase 2 | |
Not yet recruiting |
NCT05202041 -
Non-IRA Functional Evaluation With AccuFFRangio in NSTE-ACS
|
N/A | |
Recruiting |
NCT02415803 -
Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS
|
Phase 3 | |
Not yet recruiting |
NCT05779059 -
Prasugrel Or Ticagrelor De-escalation in NSTE-ACS
|
Phase 3 |